You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

53 Results
Guidelines and Advice
Mar 2025
Drug
Other Name(s): Vectibix®
Jan 2025
Drug
Other Name(s): Rituxan® , Truxima™ , Riximyo™ , Ruxience™ , Riabni™
Jun 2025
Drug
Other Name(s): Caelyx®
Sep 2025
Drug
Other Name(s): Jakavi®
Mar 2025
Drug
Other Name(s): Pomalyst®
Apr 2025
Drug
Other Name(s): Keytruda®
Sep 2025
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Funding:
New Drug Funding Program
    Liposomal DOXOrubicin - Single Agent Treatment of Platinum Sensitive Ovarian Fallopian Tube or Primary Peritoneal Cancer
New Drug Funding Program
    Liposomal Doxorubicin - Platinum-Resistant Ovarian Fallopian Tube or Primary Peritoneal Cancer
Mar 2025
Regimen
Cancer Type:
Sarcoma, 
Kaposi's Sarcoma
Intent: Palliative
Funding:
New Drug Funding Program
    Liposomal Doxorubicin - HIV-positive Kaposi's Sarcoma
Mar 2025
Regimen
Intent: Palliative
Mar 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) - Single Agent - Indolent Lymphoma
Jun 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma
Jun 2025

Pages